🇺🇸 FDA
Patent

US 10851367

Tissue-specific genome engineering using CRISPR-Cas9

granted A61KA61K47/545A61K47/549

Quick answer

US patent 10851367 (Tissue-specific genome engineering using CRISPR-Cas9) held by The Regents of the University of California expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K47/545, A61K47/549, A61P, A61P1/16